JNCCN-360

Editor:

David S. Ettinger, MD

Advertisement

Advertisement

Karen Reckamp, MD, on Metastatic NSCLC: Targeted Treatment Updates

A Patient’s Story: NCCN Guidelines for Patients® Helped Me Ask The Right Questions

Simron Singh, MD, MPH, on Patient-Centered Care: Measuring Experience

Recent

WCLC 2018: Brigatinib Poised to Become New First-Line Treatment in ALK-Positive Lung Cancer

WCLC 2018: Smoking Cessation Services During Lung Cancer Screening

WCLC 2018: Lorlatinib Active in ROS1-Positive NSCLC

International Cancer Immunotherapy Conference: Early Study Results of Vaccine in HER2-Positive Cancers

Published

Medical Literature

Impact of Neoadjuvant Erlotinib on Radical Resection Rate in Patients With NSCLC

Acquired Osimertinib Resistance in EGFR-Positive NSCLC

Does Baseline Steroid Use Impact Efficacy of Immunotherapy in Patients With NSCLC?

New Test May Help Risk Stratify Patients With NSCLC for Treatment

Ongoing

Stage III NSCLC: Practical Application of Immune Checkpoint Inhibition After Chemoradiotherapy

Management of Advanced NSCLC: Where Do Immune Checkpoint Inhibitors Fit In?:

JADPRO Regional Lectures: Immunotherapy: Case Studies in Non-Small Cell Lung Cancer

Integration of Immunotherapies Into the Treatment of Patients With Non–Small Cell Lung Cancer

Available

Clinical Trials

Robert H. Lurie Comprehensive Cancer Center of Northwestern University

UCSF Helen Diller Family Comprehensive Cancer Center

Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine

University Hospitals Seidman Cancer Center

Sections

NCCN Resources

Copyright © 2018 National Comprehensive Cancer Network, All Rights Reserved

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.